AHFS August 2024 Update

This update contains 12 new monographs and 25 revised monographs.

New monographs: Ceftobiprole Medocaril Sodium; Lidocaine (Topical); Mavorixafor; Miglustat (Pompe Disease); Motixafortide acetate; Olutasidenib; Pivmecillinam Hydrochloride; Proparacaine Hydrochloride (EENT); Quizartinib Dihydrochloride; Respiratory Syncytial Virus Vaccine (mRNA); Tarlatamab-dlle; Tetracaine Hydrochloride.

Revised monographs: Abiraterone Acetate; Alemtuzumab (Antineoplastic); Encorafenib; Entrectinib; Erdafitinib; Etanercept; Fluvastatin Sodium; Glatiramer Acetate; Ibrutinib; Isavuconazonium Sulfate; Larotrectinib Sulfate; Lenvatinib Mesylate; Leuprolide Acetate, Leuprolide Mesylate; Lovastatin; Pexidartinib Hydrochloride; Pravastatin Sodium; rifAXIMin; Rimegepant Sulfate; Ripretinib; Risankizumab-rzaa; Secukinumab; Tacrolimus (Immunomodulatory Agent); Tipranavir; Trametinib Dimethyl Sulfoxide; Tretinoin (Systemic).